Purpose: The aim of the study was to determine whether celiac disease affects ovarian reserve assessed by antral follicle counting, ovarian volume, and anti-müllerian hormone in adolescent patients.
Methods: This case-control multicenter trial was performed from January 1, 2017 to May 31, 2018 and included 45 girls. On days 2-5 of the menstrual cycle, measurements of serum follicle stimulating hormone, luteinizing hormone, estradiol, prolactin, and anti-müllerian hormone were performed. Antral follicle counts and ovarian volumes were determined on the same day.
Results: Evaluation was made of 21 (47.7%) celiac patients with a mean age of 15.8 ± 1.3 years, and 24 (52.3%) healthy control subjects with a mean age of 16.2 ± 1.2. There was no difference between the groups in respect of right and left ovarian volumes (p = 0.790 and p = 0.670, respectively). Serum levels of anti-müllerian hormone of the celiac patients and controls were found comparable [(3.7 ± 2.9 (0.5-12) and 3.6 ± 1.8 (1.2-8.1)] ng/mL, respectively, p = 0.915).
Conclusions: Celiac disease may not affect the ovarian reserve determined with established ovarian reserve markers including antral follicle counting, ovarian volume, and anti-müllerian hormone in adolescent patients.
Trial Registration: ClinicalTrials.gov identifier (NCT number): NCT04024449 https://clinicaltrials.gov/ct2/show/NCT04024449.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00404-020-05666-4 | DOI Listing |
Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group.
Materials And Methods: This retrospective cohort study involved 165 POR patients aged 18-45 years who underwent IVF between 2018 and 2022.
F S Sci
January 2025
Gynecology Research Unit, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium; Gynecology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium. Electronic address:
Objective: To establish a murine model of chemotherapy-induced diminished ovarian reserve (DOR) and investigate residual fertility after chemotherapy exposure.
Design: Two different chemotherapy protocols were tested to establish a valid DOR model by comparing follicle densities in mice given either protocol versus physiological solution. An ovarian stimulation protocol was then selected from among different gonadotropins by counting the number of day-2 embryos obtained from normal mice.
Int J Mol Sci
December 2024
Department of Physiological Sciences, Interinstitutional Post-Graduate Program of Physiological Sciences, Federal University of São Carlos (UFSCar), São Carlos 13.566-490, SP, Brazil.
Menopause occurs due to the depletion of the ovarian reserve, leading to a progressive decline in estrogen (E2) levels. This decrease in E2 levels increases the risk of developing several diseases and can coexist with chronic kidney disease (CKD). Arterial hypertension (AH) is another condition associated with menopause and may either contribute to or result from CKD.
View Article and Find Full Text PDFJ Cell Biochem
January 2025
Department of Integrated Traditional Chinese Medicine and Western Medicine, The Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Gengnianchun (GNC) is a traditional remedy used for diminished ovarian reserve, but its underlying mechanisms remain unclear. This study aimed to explore these mechanisms in human granulosa-like cancer (KGN) cells pretreated with medicated rat serum (MRS) before HO exposure. MRS pretreatment significantly alleviated HO-induced cell damage, including improvements in cell viability, superoxide dismutase and GSH-Px activities, and Bcl-2 expression.
View Article and Find Full Text PDFJ Ovarian Res
January 2025
Reproductive Health Research Center, Clinical Research Institute, Urmia University of Medical Sciences, Urmia, Iran.
Background: To investigate the impact of Melatonin on follicular oxidative stress and assisted reproductive technology (ART) outcomes in women with diminished ovarian reserve (DOR).
Method: We put 68 women with DOR who were going through ART into a randomized controlled trial. Starting on the fifth day of their menstrual cycle, we gave them either 3 mg of Melatonin or a placebo every day before stimulating their ovaries.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!